$STNE

Why is StoneCo stock sliding today?

StoneCo Ltd shares fell 2% in after-hours after its Q2 2026 results beat adjusted EPS but missed revenue. Adjusted EPS was R$2.40, in line with consensus, while revenue was R$3.59B vs R$3.67B expected. Adjusted net income fell 2.6% YoY to R$582.7M. Investors cited a 107.5% YoY jump in its credit portfolio and concerns tied to Brazil’s high rates.

Original reporting
Published Aug 13, 2026, 9:51 PM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 13, 2026, 10:15 PM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefEarnings
Primary signal
$STNE
Bearish
medium confidence
Mentioned
$STNE
Relevance
7/10
alphai data visualization · based on investing.com
Decision brief

The 30-second read

$STNEBearishMed
01

Why it matters

Traders may reprice near-term earnings durability and credit-loss provisioning risk, especially if the company’s guidance assumed a lower rate environment than current conditions.

02

Market read

A concrete earnings datapoint (revenue miss) combined with a specific balance-sheet risk factor (credit portfolio up 107.5% YoY) is the core driver of the move.

03

What to watch

The article does not provide asset quality metrics (delinquencies, loss rates) or management commentary on credit underwriting, which could materially change the risk assessment.

Relevance 7/10Novelty 6/10Timing: after-hours reaction to Q2 results

Background

The piece frames StoneCo’s after-hours drop as driven by a revenue miss and concerns around rapid credit portfolio growth amid Brazil’s still-high real rates.

Company-level read

Ticker impact

$STNEBearishMedium confidence
Context

StoneCo shares fell after Q2 results beat EPS but missed revenue, while credit portfolio growth accelerated and profitability declined year over year.

Expected impact

Further downside risk toward/through the 52-week low if investors keep questioning credit-book quality and margin durability.

Evidence & confidence

The article cites a specific revenue shortfall, declining adjusted net income, and a 107.5% YoY jump in the credit portfolio, all tied to elevated funding and provision risk.

Market effects

Highlights merchant acquiring and credit-book sensitivity to Brazil interest rates, potentially pressuring peers with similar credit exposure.

Reinforces that Brazil’s high real borrowing costs can quickly translate into higher funding and credit-loss provisions for fintech lenders.

Limited direct spillover, but it can affect investor risk appetite for LATAM consumer-credit and payments credit models.

Counterpoint

EPS met consensus and the credit book expansion could support future revenue, so the selloff may over-discount execution if take rates stabilize.

Key entities

  • StoneCo Ltd

    Brazil-focused payments and merchant acquiring company whose Q2 2026 results and credit portfolio growth drove the stock’s after-hours decline.

  • Brazil central bank (Selic)

    Trimmed Selic to 14%, but the article notes real borrowing costs remain among the highest globally.

Related articles

$SLFMed

Street Calls of the Week By Investing.com

Investing.com’s weekly Wall Street recap covers downgrades: Evercore cut Sun Life Financial (SLF) to Inline, citing valuation upside tapped out and operational friction, with a $111 target. Mizuho downgraded Circle Internet (CRCL) to Underperform, $50 target, on stablecoin margin pressure. BofA lowered StoneCo (STNE) to Neutral, $13, on Brazil rate-driven credit risk. BTIG downgraded Etsy (ETSY) to Neutral. Goldman downgraded Regions Financial (RF) to Neutral, $36, citing weaker buybacks and gui

$GSKMed

Could GSK plc (GSK)’s Pipeline Acceleration Unlock a New Growth Era?

GSK plc reported Q2 results on July 28. Total turnover was £8.4bn, up 5% CER. Core operating profit rose 7% CER to £2.80bn and Core EPS increased 9% CER to 50.5p, driven by Specialty Medicines and Vaccines. Total operating profit fell 75% CER due to a £1.3bn non-cash impairment after discontinuing camlipixant. GSK also outlined a 2026 Phase III acceleration plan and a £1.9bn annual cost-savings restructuring program.

$BFRIMedAI 8/10

Biofrontera Posts Strong Q2 2026 Results On 33% Revenue Growth

Biofrontera (BFRI) reported Q2 2026 net product revenue of $12.0M, up 32.9% from $9.0M, with gross margin rising to 80% from 71%. Net loss narrowed to $0.6M from $5.3M. For six months, revenue was $22.1M (+25.4%) and gross margin 80%. A PDUFA decision for Ameluz is expected Sept. 28, 2026.

$UPWKMedAI 8/10

Why Upwork (UPWK) Stock Is Nosediving

Upwork (UPWK) shares fell about 10% after the company reported Q2 results that beat estimates but issued weaker full-year revenue and EPS guidance. Analysts at Scotiabank and RBC cut price targets to $10 and $9 from $15 and $20, respectively, while keeping Sector Perform ratings. The stock is down sharply year to date amid AI and labor-market concerns.

$ARMKMedAI 8/10

Why Aramark (ARMK) Stock Is Up Today

Aramark (NYSE:ARMK) shares rose about 9.8% after the company reported better-than-expected Q3 2026 results. Revenue was $5.06B, up 9.3% year over year, and adjusted EPS was $0.52 above consensus. Free cash flow turned positive at $8.69M versus a $33.55M loss a year earlier.